buspirone has been researched along with Esophageal Dysmotility in 3 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Buspirone is a serotonin modulating medication and has been shown to augment esophageal peristaltic amplitude in healthy volunteers." | 2.87 | A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility. ( Aggarwal, N; Gabbard, S; Lopez, R; Thota, PN, 2018) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 2 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aggarwal, N | 1 |
| Thota, PN | 1 |
| Lopez, R | 1 |
| Gabbard, S | 1 |
| Karamanolis, GP | 1 |
| Panopoulos, S | 1 |
| Denaxas, K | 1 |
| Karlaftis, A | 1 |
| Zorbala, A | 1 |
| Kamberoglou, D | 1 |
| Ladas, SD | 1 |
| Sfikakis, PP | 1 |
| Blonski, W | 1 |
| Vela, MF | 1 |
| Freeman, J | 1 |
| Sharma, N | 1 |
| Castell, DO | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Long Term Effect of Buspirone on Esophageal Function and Esophageal Symptoms in Patients With Systematic Sclerosis (SSc)[NCT02363478] | Early Phase 1 | 22 participants (Actual) | Interventional | 2014-12-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration
| Intervention | sec (Mean) |
|---|---|
| Buspirone | 0.5 |
(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration
| Intervention | cm/sec (Mean) |
|---|---|
| Buspirone | 0.3 |
(NCT02363478)
Timeframe: before and after 4 weeks buspirone administration
| Intervention | mmHg (Mean) | |||
|---|---|---|---|---|
| amplitude | LES resting pressure | LES residual pressure | IRP | |
| Buspirone | 0.9 | 4.5 | 0.3 | 0.4 |
Severity of esophageal symptoms (dysphagia, heartburn, regurgitation and chest pain) was measured on a 100-point visual analogue scale (VAS) ranging from 0 (absent) to 100 (very severe). Even minor decrease in the VAS score for each symptom at week 4 considered as improvement. (NCT02363478)
Timeframe: before and after 4 weeks buspirone administration
| Intervention | units on a scale (Mean) | |||
|---|---|---|---|---|
| heartburn | regurgitation | dysphagia | chest pain | |
| Buspirone | 14.9 | 13.2 | 6.9 | 1.9 |
3 trials available for buspirone and Esophageal Dysmotility
| Article | Year |
|---|---|
A randomized double-blind placebo-controlled crossover-style trial of buspirone in functional dysphagia and ineffective esophageal motility.
Topics: Buspirone; Cross-Over Studies; Double-Blind Method; Esophageal Motility Disorders; Female; Humans; M | 2018 |
The 5-HT1A receptor agonist buspirone improves esophageal motor function and symptoms in systemic sclerosis: a 4-week, open-label trial.
Topics: Adult; Aged; Buspirone; Esophageal Motility Disorders; Esophagus; Female; Humans; Male; Manometry; M | 2016 |
The effect of oral buspirone, pyridostigmine, and bethanechol on esophageal function evaluated with combined multichannel esophageal impedance-manometry in healthy volunteers.
Topics: Administration, Oral; Adult; Bethanechol; Buspirone; Cholinesterase Inhibitors; Cross-Over Studies; | 2009 |